RenovoRx (RNXT) Competitors $1.25 +0.10 (+8.70%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RNXT vs. ABOS, MGX, LPTX, TARA, INMB, JMAC, XFOR, ADVM, CRDL, and MNOVShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Acumen Pharmaceuticals (ABOS), Metagenomi (MGX), Leap Therapeutics (LPTX), Protara Therapeutics (TARA), INmune Bio (INMB), Maxpro Capital Acquisition (JMAC), X4 Pharmaceuticals (XFOR), Adverum Biotechnologies (ADVM), Cardiol Therapeutics (CRDL), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. RenovoRx vs. Acumen Pharmaceuticals Metagenomi Leap Therapeutics Protara Therapeutics INmune Bio Maxpro Capital Acquisition X4 Pharmaceuticals Adverum Biotechnologies Cardiol Therapeutics MediciNova Acumen Pharmaceuticals (NASDAQ:ABOS) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Which has more risk & volatility, ABOS or RNXT? Acumen Pharmaceuticals has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Is ABOS or RNXT more profitable? Acumen Pharmaceuticals' return on equity of -32.99% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -32.99% -27.99% RenovoRx N/A -205.96%-110.01% Do insiders and institutionals have more ownership in ABOS or RNXT? 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ABOS or RNXT? Acumen Pharmaceuticals received 16 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 71.43% of users gave Acumen Pharmaceuticals an outperform vote while only 47.37% of users gave RenovoRx an outperform vote. CompanyUnderperformOutperformAcumen PharmaceuticalsOutperform Votes2571.43% Underperform Votes1028.57% RenovoRxOutperform Votes947.37% Underperform Votes1052.63% Which has higher valuation & earnings, ABOS or RNXT? RenovoRx is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$52.37M-$1.38-1.34RenovoRxN/AN/A-$10.23M-$0.57-2.19 Does the media favor ABOS or RNXT? In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than RenovoRx. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 0 mentions for RenovoRx. Acumen Pharmaceuticals' average media sentiment score of 0.97 beat RenovoRx's score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acumen Pharmaceuticals Positive RenovoRx Neutral Do analysts rate ABOS or RNXT? Acumen Pharmaceuticals presently has a consensus price target of $9.33, indicating a potential upside of 404.50%. RenovoRx has a consensus price target of $6.50, indicating a potential upside of 420.00%. Given RenovoRx's higher probable upside, analysts plainly believe RenovoRx is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAcumen Pharmaceuticals beats RenovoRx on 10 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.00M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio-2.1910.5089.8217.18Price / SalesN/A195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book-4.465.094.784.78Net Income-$10.23M$151.83M$120.23M$225.60M7 Day Performance-2.34%-2.13%-1.92%-1.23%1 Month PerformanceN/A-3.10%11.49%3.36%1 Year Performance47.11%11.54%30.57%16.60% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx1.2324 of 5 stars$1.25+8.7%$6.50+420.0%+76.1%$30.00MN/A-2.196Positive NewsGap UpABOSAcumen Pharmaceuticals3.1582 of 5 stars$1.97-3.0%$9.33+373.8%-39.9%$118.36MN/A-1.4751Short Interest ↓News CoverageMGXMetagenomi2.1309 of 5 stars$3.11-4.0%$16.67+435.9%N/A$116.39M$55.08M0.00236High Trading VolumeLPTXLeap Therapeutics1.2897 of 5 stars$3.01+2.0%$7.50+149.2%-1.0%$115.34M$1.50M-1.5340Positive NewsGap DownTARAProtara Therapeutics2.3557 of 5 stars$5.53-7.5%$22.67+309.9%+196.2%$114.08MN/A-1.8830INMBINmune Bio1.4805 of 5 stars$5.08+6.9%$20.00+293.7%-55.7%$112.63M$42,000.00-2.3310JMACMaxpro Capital AcquisitionN/A$8.34+7.8%N/A+837.6%$112.00MN/A0.002,021Gap DownXFORX4 Pharmaceuticals4.3341 of 5 stars$0.65-3.8%$3.50+442.6%-16.4%$110.01MN/A-8.2280Gap DownADVMAdverum Biotechnologies4.2094 of 5 stars$5.26-2.0%$27.83+429.2%-40.0%$109.42M$1M-0.90190Analyst DowngradeNews CoverageCRDLCardiol Therapeutics2.2579 of 5 stars$1.33flat$8.75+557.9%+44.0%$108.67M$60,000.00-3.4120Analyst ForecastAnalyst RevisionNews CoverageGap DownMNOVMediciNova2.1642 of 5 stars$2.11+0.5%$9.00+326.5%+43.7%$103.49M$1M-9.9510Analyst ForecastPositive News Related Companies and Tools Related Companies ABOS Alternatives MGX Alternatives LPTX Alternatives TARA Alternatives INMB Alternatives JMAC Alternatives XFOR Alternatives ADVM Alternatives CRDL Alternatives MNOV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNXT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNXT Stock Alerts